US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| TASMAR | 100MG; 200MG | tablet · oral | BAUSCH | Discontinued | 29 Jan 1998 |
| TOLCAPONE | 100MG | tablet · oral | PH HEALTH | Discontinued | 26 Mar 2015 |
| TOLCAPONE | 100MG | tablet · oral | INGENUS PHARMS LLC | Discontinued | 7 Aug 2018 |
| TOLCAPONE | 100MG | tablet · oral | DR REDDYS LABS SA | Discontinued | 1 Aug 2019 |
| TOLCAPONE | 100MG | tablet · oral | ALVOGEN | Discontinued | 29 Jul 2020 |
EMA European Union — centrally authorised medicines
Tasmar Viatris Healthcare Limited · Authorised · authorised 27 Aug 1997 · ATC N04BX01
Therapeutic indication (EMA)
Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors. Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa. Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar.
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| NHS Drug Tariff | Tolcapone 100mg tablets | £95.20 | 100 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.